Characteristics | Values |
---|---|
Male sex, n (%) | 89 (50.57) |
Age, y | 53.90 ± 14.26 (51.78–56.03) |
BMI, kg/m2 | 24.56 ± 3.94 (23.98–25.15) |
Positive smoking statusa, n (%) | 55 (31.25) |
Smoking indexb, pack-years | 10.00 (8.00,14.00) |
Duration of asthma, y | 6.50 (2.00,18.00) |
NPs, n (%) | 82 (46.59) |
Prior sinus surgery, n (%) | 34 (19.32) |
Allergic rhinitis, n (%) | 112 (63.64) |
Atopic dermatitis, n (%) | 14 (7.95) |
Gastroesophageal reflux disease, n (%) | 14 (7.95) |
ICS dose (fluticasone equivalent), μg/d | 320.00 (160.00, 320.00) |
Severe asthma, n (%) | 26 (14.77) |
≥ 1 severe exacerbation of asthma in the last 12 months, n (%) | 54 (30.68) |
≥ 1 pneumonia in the last 12 months, n (%) | 51 (28.98) |
Peripheral blood eosinophil counts, × 109/L | 0.37 (0.20,0.70) |
FeNO, ppb | 36.50 (18.00, 66.00) |
Total IgE, IU/mL | 177.00 (48.83, 356.50) |
Atopy, n (%) | 91 (51.70) |
Postbronchodilator FEV1% predicted, % | 79.10 ± 19.91 (76.13–82.06) |
LM scores | 10.00 (6.00, 17.00) |
Bronchiectasis in HRCT, n (%) | 72 (40.91) |